Skip to content
DataLookout
Menu

SIREC-PoumonNCT07904013

Impact of a Radiologic and Immunologic Signature on Cerebral Efficacy of Treatments in Lung Cancers With Brain Metastasis

StatusNot Yet Recruiting
PhaseNot specified
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Correlation between MRI-based radiomic signature and transcriptomic signature of brain metastases
Timeframe: At diagnosis, before treatment initiation

Secondary (1)

Correlation between radiomic signature and cerebral progression free survival (PFS) / correlation between transcriptomic signature and cerebral PFS / correlation between immunoradiomic signature and cerebral PFS

Arms and interventions

Patients with brain metastases from NSCLC

Patients aged 18 years or older with advanced or metastatic non-small cell lung cancer, at least one resected brain metastasis at diagnosis, and an indication for first-line immunotherapy plus chemotherapy

Other: Radiomic analysis; Bulk RNA sequencing

Sites

1 site in 1 country

  • CHU de Bordeaux, Hôpital Saint-AndréBordeaux, France